SUPPORTIVE CARE: ORIGINAL ARTICLE |
|
Year : 2017 | Volume
: 6
| Issue : 1 | Page : 20-24 |
|
Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
Vineet Talwar1, Sharanabasappa S Nirni2, Krishna Mohan Mallavarapu3, Anupama Ramkumar4, Nitu Sinha4
1 Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India 2 Medical Oncology, Omega Hospitals, Hyderabad, India 3 Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India 4 Clinical Development, Biologics, Dr. Reddy's Laboratories Ltd., Hyderabad, India
Correspondence Address:
Nitu Sinha Clinical Development, Biologics, Dr. Reddy's Laboratories Ltd., Hyderabad India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2278-330X.202560
|
|
Background: A granulocyte colony-stimulating factor, pegfilgrastim, is efficacious though expensive for prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia. Biologics available and accessible today, having acceptable safety-efficacy profiles, require postapproval studies for better understanding of such drugs in clinical settings. Aim: This postmarketing surveillance study evaluated the safety of prophylactic Peg-grafeel™ (pegfilgrastim) in cancer patients with chemotherapy-induced neutropenia. Settings and Design: This prospective, noninterventional, single-arm, open-label study was conducted at 10 study sites in India. Methods: Patients received subcutaneous 6 mg Peg-grafeel™ approximately 24 h following chemotherapy as part of routine patient care. Statistical Analysis: Data were summarized descriptively. Results: The study included 250 patients (male: female = 36.4%:63.6%; median age, 54 [16–80] years). Most patients had Stage III (33.2%) or IV (41.6%) cancers and received cyclophosphamide (37.2%) and doxorubicin (31.6%) as chemotherapy. On an average, 4 Peg-grafeel™ doses were administered per patient. Treatment-emergent adverse events (AEs) were reported in 115 (46%) patients, the most common being vomiting (11.6%), pain (11.2%), nausea (8.4%), and constipation (8.4%). Peg-grafeel™-related AEs included pain (3.2%), asthenia (2.4%), and arthralgia (1.2%). Bone pain (0.4%) and extremity pain (1.2%) were rare. Grade 3/4 neutropenia and febrile neutropenia occurred in 4 (1.6%) and 3 (1.2%) patients, respectively. Serious AEs included vomiting (2.8%) and pyrexia (2%). No new safety concerns were identified. None of the five deaths was considered related to Peg-grafeel™. Conclusion: The overall safety profile of Peg-grafeel™ was consistent with the expected safety profile of pegfilgrastim in patients with advanced malignancies in a clinical setting. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|